Information Provided By:
Fly News Breaks for March 3, 2020
MDRX
Mar 3, 2020 | 05:02 EDT
Piper Sandler analyst Sean Wieland lowered the firm's price target on Allscripts to $9.50 from $12 and keeps a Neutral rating on the shares. The company missed Q4 revenue estimates and guided 2020 below consensus, Wieland tells investors in a research note. The 2019 results and 2020 guidance render Allscripts's 2019-2021 non-GAAP organic revenue target unachievable, adds the analyst.
News For MDRX From the Last 2 Days
There are no results for your query MDRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.